These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 4006813)

  • 1. Serious side effects of oxamniquine during the treatment of Schistosoma mansoni in Kenya.
    Chunge CN; Kimani RG; Gachihi G; Mkoji G; Kamau T; Rashid JR
    East Afr Med J; 1985 Jan; 62(1):3-4. PubMed ID: 4006813
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: serious side effects of oxamniquine during the treatment of Schistosoma mansoni in Kenya.
    Okela GB
    East Afr Med J; 1985 Jul; 62(7):433. PubMed ID: 3935408
    [No Abstract]   [Full Text] [Related]  

  • 3. A study of chromosomes of schistosomiasis patients under oxaminiquine (UK 4271) treatment.
    Monsalve MV; Frota-Pessoa O; Campos AM; Sette H
    J Toxicol Environ Health; 1976 Jul; 1(6):1023-6. PubMed ID: 966313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxamniquine and fever.
    Jordan P
    Br Med J; 1979 Nov; 2(6201):1366-7. PubMed ID: 519455
    [No Abstract]   [Full Text] [Related]  

  • 5. Observations of the treatment of mansoni schistosomiasis with oxamniquine: efficacy in children and in persistent salmonellosis; resistance of a strain of Schistosoma mansoni; hepatic toxicity and neurological side effects.
    Pedro Rde J; de Souza Dias LC; Amato Neto V; de Carvalho SA
    Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):32-6, 148-52. PubMed ID: 7455507
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and toxicity of oxamniquine in the treatment of Schistosoma mansoni infections, with particular reference to electroencephalographic abnormalities.
    Krajden S; Keystone JS; Glenn C
    Am J Trop Med Hyg; 1983 Nov; 32(6):1344-6. PubMed ID: 6650735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxamniquine (Vansil) in the treatment of Schistosoma mansoni infections in Rhodesia.
    de V Clarke V
    Cent Afr J Med; 1977 Nov; 23(11 Suppl):20-3. PubMed ID: 606374
    [No Abstract]   [Full Text] [Related]  

  • 8. [Therapeutic evaluation of oxamniquine in schistosomiasis mansoni].
    de Almeida FM; Vilela MP; Pricoli TI; Salem N; Guimarães RX; Ferraz CN; Arroyo JB; Fukuda Y; Cabeca M; Geocze S; Tancredi Neto A
    AMB Rev Assoc Med Bras; 1979 Mar; 25(3):101-4. PubMed ID: 315583
    [No Abstract]   [Full Text] [Related]  

  • 9. A preliminary report on the treatment of intestinal schistosomiasis with oxamniquine.
    Shafei AZ
    J Trop Med Hyg; 1979 Jan; 82(1):18-20. PubMed ID: 448786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of mansonic schistosomiasis with oxamniquine (UK-4271)].
    Huggins D
    An Inst Hig Med Trop (Lisb); 1977-1978; 5(1-4):215-20. PubMed ID: 553457
    [No Abstract]   [Full Text] [Related]  

  • 11. Observations on the treatment of mansoni schistosomiasis with oxamniquine.
    Pedro RD; Dias LC; Amato Neto V; De Carvalho SA
    Rev Bras Pesqui Med Biol; 1979 Jun; 12(2-3):207-11. PubMed ID: 515473
    [No Abstract]   [Full Text] [Related]  

  • 12. The treatment of schistosomiasis mansoni in Murang'a District, Kenya: a double blind controlled trial of three hycanthone regimens and oxamniquine.
    Rees PH; Bowry HN; Roberts JM; Thuku JJ
    Am J Trop Med Hyg; 1975 Sep; 24(5):823-6. PubMed ID: 1190368
    [No Abstract]   [Full Text] [Related]  

  • 13. A fifteen-month study on the efficacy of a single 15 mg/kg dose of oxamniquine (Vansil) in Schistosoma mansoni in an endemic area.
    Nozais JP
    Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):52-7, 168-74. PubMed ID: 6256843
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial with oxamniquine and praziquantel in the acute and chronic phases of schistosomiasis mansoni.
    Katz N; Rocha RS; Lambertucci JR; Greco DB; Pedroso ER; Rocha MO; Flan S
    Rev Inst Med Trop Sao Paulo; 1983; 25(4):173-7. PubMed ID: 6361966
    [No Abstract]   [Full Text] [Related]  

  • 15. [Neurotoxicity of oxamniquine in the treatment of human Schistosoma mansoni infection].
    de Carvalho SA; Shikanai-Yasuda MA; Amato Neto V; Shiroma M; Luccas FJ
    Rev Inst Med Trop Sao Paulo; 1985; 27(3):132-42. PubMed ID: 3938063
    [No Abstract]   [Full Text] [Related]  

  • 16. Double-blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni.
    Katz N; Rocha RS
    Rev Inst Med Trop Sao Paulo; 1982; 24(5):310-4. PubMed ID: 6762634
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind clinical trial comparing praziquantel with oxamniquine in the treatment of patients with schistosomiasis mansoni.
    Branchini ML; Pedro Rde J; Dias LC; Deberaldini ER
    Rev Inst Med Trop Sao Paulo; 1982; 24(5):315-21. PubMed ID: 6762635
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term hepatocellular effects of hycanthone and of two other anti-Schistosomal drugs in mice infected with Schistosoma mansoni.
    Haese WH; Bueding E
    J Pharmacol Exp Ther; 1976 Jun; 197(3):703-13. PubMed ID: 180276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-finding trials of oral oxamniquine in Rhodesia.
    de V Clarke V; Blair DM; Weber MC; Garnett PA
    S Afr Med J; 1976 Oct; 50(46):1867-71. PubMed ID: 996687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of oxamniquine in Egypt.
    Saif M; Gaber A
    Rev Inst Med Trop Sao Paulo; 1980; 22(1 Suppl 4):18-27, 134-43. PubMed ID: 7455504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.